A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC)

被引：1

作者：

Moreno, V. ^{[1
]}

Bauer, T. M. ^{[2
]}

Infante, J. ^{[3
]}

Govindan, R. ^{[4
]}

Besse, B. ^{[5
]}

Bertino, E. ^{[6
]}

Martinez Marti, A. ^{[7
]}

Piontek, T. ^{[8
]}

Dhar, A. ^{[9
]}

机构：

[1] Fdn Jimenez Diaz Hosp, START Madrid FJD, Med Oncol, Madrid, Spain

[2] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

[3] Sarah Cannon Res Inst, Other, Nashville, TN USA

[4] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA

[5] Inst Gustave Roussy, Dept Med, Villejuif, France

[6] Ohio State Univ, Med Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA

[7] Vall dHebron Univ Hosp, Inst Oncol, Med Oncol, Barcelona, Spain

[8] GlaxoSmithKline, RD Projects Clin Platforms & Sci, Collegeville, PA USA

[9] GlaxoSmithKline, Onocolgy R&D, Collegeville, PA USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw368.24

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

381P

引用

页数：1

共 50 条

[41] IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician's choice (TPC) in relapsed small cell lung cancer (SCLC) [J].

Owonikoko, Taofeek K. ;

Byers, Lauren Averett ;

Cheng, Ying ;

Hayashi, Hidetoshi ;

Paz-Ares, Luis G. ;

Perol, Maurice ;

Turner, Jennifer ;

Qian, Meng ;

Garcia, Cecilio Roi ;

Godard, Juliette ;

Rudin, Charles M. .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[42] Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study [J].

Hutchings, Martin ;

Mous, Rogier ;

Clausen, Michael Roost ;

Johnson, Peter ;

Linton, Kim M. ;

Chamuleau, Martine E. D. ;

Lewis, David John ;

Balari, Anna Sureda ;

Cunningham, David ;

Oliveri, Roberto S. ;

Elliott, Brian ;

DeMarco, Dena ;

Azaryan, Ada ;

Chiu, Christopher ;

Li, Tommy ;

Chen, Kuo-mei ;

Ahmadi, Tahamtan ;

Lugtenburg, Pieternella J. .

LANCET, 2021, 398 (10306) :1157-1169

[43] A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies [J].

Patel, Manish ;

Hamlin, Paul ;

Strickland, Donald K. ;

Pandey, Anjali ;

Coffey, Greg ;

Leeds, Janet M. ;

Levy, Gallia G. ;

Curnutte, John T. ;

Wagner-Johnston, Nina ;

Flinn, Ian W. .

BLOOD, 2014, 124 (21)

[44] Results of an Open-Label Phase 1 Study Repurposing Oral Metformin and Nelfinavir in Combination with Subcutaneous Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma [J].

Alodhaibi, Ibrahim ;

Ailawadhi, Sikander ;

Burbano, Gaby E. Perez ;

O'Brien, Patrick ;

Buadi, Francis ;

Hayman, Suzanne R. ;

Kumar, Shaji Kunnathu ;

Gonsalves, Wilson I. .

BLOOD, 2023, 142

[45] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study [J].

Hamadani, Mehdi ;

Collins, Graham P. ;

Caimi, Paolo F. ;

Samaniego, Felipe ;

Spira, Alexander ;

Davies, Andrew ;

Radford, John ;

Menne, Tobias ;

Karnad, Anand ;

Zain, Jasmine M. ;

Fields, Paul ;

Havenith, Karin ;

Cruz, Hans G. ;

He, Shui ;

Boni, Joseph ;

Feingold, Jay ;

Wuerthner, Jens ;

Horwitz, Steven .

LANCET HAEMATOLOGY, 2021, 8 (06) :E433-E445

[46] Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer [J].

Chiang, Anne C. ;

Sequist, Lecia Van Dam ;

Gilbert, Jill ;

Conkling, Paul ;

Thompson, Dana ;

Marcoux, J. Paul ;

Gettinger, Scott ;

Kowanetz, Marcin ;

Molinero, Luciana ;

O'Hear, Carol ;

Fasso, Marcella ;

Lam, Sivuonthanh ;

Gordon, Michael S. .

CLINICAL LUNG CANCER, 2020, 21 (05) :455-+

[47] ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE 1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND *DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA [J].

Magarotto, V. ;

Sonneveld, P. ;

Voorhees, P. ;

Paba-Prada, C. ;

Plesner, T. ;

Mellqvist, U. H. ;

Byrne, C. ;

Harmenberg, J. ;

Nordstrom, E. ;

Palumbo, A. ;

Richardson, P. .

HAEMATOLOGICA, 2015, 100 :89-89

[48] AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM) [J].

Mellqvist, U. H. ;

Paba-Prada, C. ;

Palumbo, A. ;

Plesner, T. ;

Sonneveld, P. ;

Voorhees, P. ;

Byrne, C. ;

Harmenberg, J. ;

Nordstrom, E. ;

Richardson, P. G. .

HAEMATOLOGICA, 2014, 99 :375-376

[49] Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients [J].

Ellis, Peter M. ;

Kaiser, Rolf ;

Zhao, Yihua ;

Stopfer, Peter ;

Gyorffy, Steve ;

Hanna, Nasser .

CLINICAL CANCER RESEARCH, 2010, 16 (10) :2881-2889

[50] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study [J].

Plesner, Torben ;

Arkenau, Hendrik-Tobias ;

Gay, Francesca Marianatal ;

Minnema, Monique C. ;

Boccadoro, Mario ;

Moreau, Philippe ;

Cavenagh, James D. ;

Perrot, Aurore ;

Laubach, Jacob ;

Ahmadi, Tahamtan ;

de Boer, Carla ;

Chen, Diana ;

Chiu, Christopher ;

Schecter, Jordan ;

Richardson, Paul G. .

BLOOD, 2017, 130

← 1 2 3 4 5 →